| Literature DB >> 26604824 |
Morten Schmidt1, Sigrun Alba Johannesdottir Schmidt1, Jakob Lynge Sandegaard2, Vera Ehrenstein1, Lars Pedersen1, Henrik Toft Sørensen1.
Abstract
BACKGROUND: The Danish National Patient Registry (DNPR) is one of the world's oldest nationwide hospital registries and is used extensively for research. Many studies have validated algorithms for identifying health events in the DNPR, but the reports are fragmented and no overview exists.Entities:
Keywords: epidemiological methods; medical record linkage; registries; research design; validation studies
Year: 2015 PMID: 26604824 PMCID: PMC4655913 DOI: 10.2147/CLEP.S91125
Source DB: PubMed Journal: Clin Epidemiol ISSN: 1179-1349 Impact factor: 4.790
Aims of the Danish National Patient Registry
| 1. Form the basis for the Danish Health and Medicines Authority’s hospital statistics |
| 2. Form the basis for health economic calculations |
| 3. Provide the Danish authorities with data to support hospital planning |
| 4. Provide data to support the authorities responsible for hospital inspection |
| 5. Monitor the frequency of various diseases and treatments |
| 6. Provide a sampling frame for longitudinal population-based and clinical research |
| 7. Facilitate quality assurance of Danish health care services |
| 8. Provide hospital physicians with access to patient’s hospitalization histories |
Content of the Danish National Patient Registry
| CPR number | Unique ten-digit personal identification number assigned at birth or upon emigration |
| Residence | Municipality and region of residence |
| Hospital and department | Hospital and department admitting the patient |
| Patient contact | Inpatient, outpatient (ambulatory), or emergency department contacts |
| Admission type | Acute or nonacute |
| Referred from/referred to | General practitioner, outpatient (ambulatory) clinic, other hospital departments, foreign hospital, no referral (eg, acute admission via ambulance), or death (only applies to “referred to” if death is declared during admission) |
| Referral period | Period from referral date to start date for hospital contact |
| Waiting time | Period from referral date to start date for treatment |
| Contact reason | Reason for the hospital contact: diagnosis, accident, act of violence, suicide attempt, late complications, unknown (eg, unconscious patient), or other (rarely used) |
| Accident | Accident description, when an accident is the contact reason |
| Time specifications | Date and time of inpatient admission/discharge, start/end date for outpatient treatment, date of arrival to/discharge from emergency department, and date of referral (if relevant) |
| Other administrative data | Home visit (AAF6) or out-of-home visit (eg, drop-in center or prison service; AAF7) Treatment status of cancers covered by national treatment guaranties: referred, examined, or under treatment |
| Primary diagnosis | Main reason for hospitalization. When a patient is being examined and a diagnosis is not yet confirmed, a tentative “obs pro” (observation for) diagnosis may be used (the ICD-10 “Z-codes”) |
| Secondary diagnoses | Optional diagnoses supplementing the primary diagnosis by, eg, describing the underlying chronic disease that is related to the current patient contact |
| Referral diagnosis | Diagnosis given by referring unit as the reason for referral |
| Temporary diagnoses | Diagnoses used only for ongoing nonpsychiatric outpatient contacts and never for completed contacts or for psychiatric contacts |
| Complications | Procedure-related complications, eg, perioperative bleeding or postoperative infections |
| Supplementary codes | Up to 50 codes supplementing the primary diagnosis, typically tentative diagnoses (eg, adding meningitis examination to the primary diagnosis disease of the central nervous system), drug abuse (eg, adding heroin to acute opioid intoxication), drug side effects (eg, adding acetylsalicylic acid to peptic ulcer disease), or cancer stage (eg, adding TNM stage to primary tumor diagnosis) |
| Surgery (K) | For example, surgery on the thyroid gland (KBA), lung (KGD), or coronary arteries (KFN) |
| Other treatments (B) | Patient care: eg, dress a wound with sterile bandage (BNPA40) or supra pubic catheter change (BJAZ14) |
| Anesthesia and intensive care (N) | For example, during intensive care (NABB) |
| Radiological procedures (U) | For example, angiography (UXA), computed tomography (UXC), magnetic resonance imaging (UXM), X-ray (UXR), and ultrasound scan (UXU) |
| Temporary examinations (W) | Temporary classification of examinations |
| Other examinations (ZZ) | For example, planning rehabilitation (ZZ0175X), distortion product otoacoustic emission (ZZ7307), and cardiotocography (ZZ4233) |
Abbreviations: CPR, Civil Personal Register; TNM, Classification of malignant tumours based on tumor size (T), lymph node involvement (N) and distant metastasis (M).
Time line for patient contact and admission types in the Danish National Patient Registry
| Code | Registration period | |
|---|---|---|
| Inpatient | 0 | Jan 1, 2002–ongoing |
| 24 hour patient | 0 | Jan 1, 1977–Dec 31, 2001 |
| Daytime patient | 1 | Jan 1, 1977–Dec 31, 1986 |
| Half-day patient | 1 | Jan 1, 1987–2001 |
| Outpatient | 2 | Jan 1, 1987–ongoing |
| Overnight patient | 2 | Jan 1, 1977–Dec 31, 1986 |
| Emergency department patient | 3 | Jan 1, 1987–Dec 31, 2013 |
| Acute | 1 | Jan 1, 1987–ongoing |
| Nonacute | 2 | Jan 1, 1987–ongoing |
Figure 1Timeline for the content and classification systems in the Danish National Patient Registry.
Abbreviations: DCECI, Danish Classification of External Causes of Injury; ed, edition; ICD, International Classification of Diseases; NCECI, Nordic Classification of External Causes of Injury; NOMESCO, Nordic Medico-Statistical Committee.
Number of patients registered in the Danish National Patient Registry according to disease categories and patient contacts, 1977–2012a
| ICD-8 | ICD-10 | Disease categories | Inpatient contact, n (%) | Outpatient contact, n (%) | Emergency department contact, n (%) | Any patient contact, n (%) |
|---|---|---|---|---|---|---|
| All | All | All diseases | 7,268,857 (100) | 5,953,405 (100) | 5,097,300 (100) | 8,085,603 (100) |
| 0–139 | A00–B99 | Certain infectious and parasitic diseases | 801,471 (11.0) | 232,080 (3.9) | 104,089 (2.0) | 975,286 (12.1) |
| 140–239 | C00–D48 | Neoplasms | 1,308,247 (18.0) | 910,226 (15.3) | 18,619 (0.4) | 1,599,930 (19.8) |
| 280–289 | D50–D89 | Diseases of the blood and blood-forming organs | 351,455 (4.8) | 146,420 (2.5) | 13,779 (0.3) | 416,132 (5.1) |
| 240–279 | E00–E90 | Endocrine, nutritional, and metabolic diseases | 972,238 (13.4) | 653,091 (11.0) | 69,610 (1.4) | 1,232,964 (15.2) |
| 290–319 | F00–F99 | Mental and behavioral disorders | 575,514 (7.9) | 218,086 (3.7) | 137,711 (2.7) | 743,981 (9.2) |
| 320–359 | G00–G99 | Diseases of the nervous system | 514,425 (7.1) | 504,543 (8.5) | 90,232 (1.8) | 840,500 (10.4) |
| 360–379 | H00–H59 | Diseases of the eye and adnexa | 295,631 (4.1) | 738,413 (12.4) | 126,565 (2.5) | 997,947 (12.3) |
| 380–389 | H60–H95 | Diseases of the ear and mastoid process | 271,495 (3.7) | 547,612 (9.2) | 42,307 (0.8) | 750,109 (9.3) |
| 390–459 | I00–I99 | Diseases of the circulatory system | 1,971,447 (27.1) | 1,106,198 (18.6) | 311,333 (6.1) | 2,312,646 (28.6) |
| 460–519 | J00–J99 | Diseases of the respiratory system | 1,738,535 (23.9) | 713,021 (12.0) | 204,853 (4.0) | 2,018,882 (25.0) |
| 520–579 | K00–K93 | Diseases of the digestive system | 1,717,940 (23.6) | 1,116,975 (18.8) | 174,675 (3.4) | 2,229,186 (27.6) |
| 680–709 | L00–L99 | Diseases of the skin and subcutaneous tissue | 421,034 (5.8) | 434,280 (7.3) | 190,607 (3.7) | 824,052 (10.2) |
| 710–739 | M00–M99 | Musculoskeletal and connective tissue disease | 1,178,743 (16.2) | 1,747,207 (29.3) | 440,731 (8.6) | 2,387,728 (29.5) |
| 580–629 | N00–N99 | Diseases of the genitourinary system | 1,527,088 (21.0) | 1,132,468 (19.0) | 123,847 (2.4) | 2,066,692 (25.6) |
| 630–679 | O00–O99 | Pregnancy, childbirth, and the puerperium | 1,287,919 (17.7) | 429,432 (7.2) | 44,587 (0.9) | 1,321,981 (16.3) |
| 760–779 | P00–P96 | Conditions originating in the perinatal period | 468,787 (6.4) | 75,901 (1.3) | 1,867 (0.0) | 490,506 (6.1) |
| 740–759 | Q00–Q99 | Congenital malformations and deformations | 274,586 (3.8) | 235,560 (4.0) | 4,116 (0.1) | 412,386 (5.1) |
| 780–799 | R00–R99 | Symptoms, signs, and findings not classified elsewhere | 1,952,537 (26.9) | 1,214,203 (20.4) | 655,075 (12.9) | 2,784,868 (34.4) |
| 800–999 | S00–T98 | External causes of injury and poisoning | 2,184,899 (30.1) | 1,751,282 (29.4) | 4,252,799 (83.4) | 5,056,701 (62.5) |
| E00–E99 | X01–Y98 | External causes of morbidity and mortality | 669,066 (9.2) | 756 (0.0) | 27,230 (0.5) | 692,424 (8.6) |
| Y00–Y99 | Z00–Z99 | Factors influencing health and contact with health services | 4,162,984 (57.3) | 4,890,778 (82.2) | 1,894,891 (37.2) | 6,104,084 (75.5) |
Notes:
The disease categories are ordered according to the ICD-10. Both primary and secondary diagnoses were included. A person (ie, one Civil Personal Register number) can contribute in several diseases categories, but only once in each cell.
Abbreviation: ICD, International Classification of Diseases.
The 25 most common ICD-10 diagnoses at the four-digit level in the Danish National Patient Registry, according to patient contact type, 1994–2012a
| Inpatient contact
| Outpatient contact
| Emergency department contact
| |||
|---|---|---|---|---|---|
| Diagnosis (ICD-10 code)
| n (%)
| Diagnosis (ICD-10 code)
| n (%)
| Diagnosis (ICD-10 code)
| n (%)
|
| Any | 4,610,123 (100) | Any | 4,995,365 (100) | Any | 4,792,298 (100) |
| 1. Spontaneous vertex delivery (O800) | 466,723 (10.1) | Senile cataract, unspecified (H259) | 287,008 (5.7) | Fracture of lower end of radius (S934) | 590,608 (12.3) |
| 2. Pneumonia, unspecified (J189) | 260,815 (5.7) | Presbycusis (H911) | 193,200 (3.9) | Open wound of finger(s) without damage to nail (S610) | 554,305 (11.6) |
| 3. Abdominal pain, unspecified (R108) | 159,390 (3.5) | Unilateral or unspecified inguinal hernia (K409) | 178,811 (3.6) | Contusion of finger(s) without damage to nail (S600) | 301,454 (6.3) |
| 4. Angina pectoris, unspecified (I209) | 147,605 (3.2) | Meniscus derangement due to tear or injury (M232) | 157,750 (3.2) | Contusion of wrist and hand, exclusion fingers (S602) | 263,753 (5.5) |
| 5. Acute abdomen (R100) | 146,264 (3.2) | Essential hypertension (I109) | 132,992 (2.7) | Fracture of lower end of radius (S525) | 250,339 (5.2) |
| 6. Atrial fibrillation and flutter (I489) | 142,849 (3.1) | Hearing loss, unspecified (H919) | 126,037 (2.5) | Contusion of knee (S800) | 243,863 (5.1) |
| 7. Concussion (S060) | 129,704 (2.8) | Fracture of lower end of radius (S525) | 123,682 (2.5) | Open wound of head, part unspecified (S019) | 242,506 (5.1) |
| 8. Syncope and collapse (R559) | 114,942 (2.5) | Complete or unspecified medical abortion (O049) | 121,821 (2.4) | Open wound of scalp (S010) | 241,943 (5.0) |
| 9. Stroke, unspecified (I649) | 112,366 (2.4) | Angina pectoris, unspecified (I209) | 120,765 (2.4) | Contusion of other and unspecified parts of foot (S903) | 204,344 (4.3) |
| 10. Gastroenteritis of unspecified origin (A099) | 107,339 (2.3) | Tear of meniscus (S832) | 117,493 (2.4) | Sprain and strain of finger(s) (S636) | 199,784 (4.2) |
| 11. Unilateral or unspecified inguinal hernia (K409) | 98,996 (2.1) | Abdominal pain, unspecified (R108) | 117,381 (2.3) | Fracture of other finger (S626) | 171,706 (3.6) |
| 12. Delivery by emergency cesarean section (O821) | 97,505 (2.1) | Varicose veins of lower extremities (I839) | 116,957 (2.3) | Contusion of shoulder and upper arm (S400) | 169,022 (3.5) |
| 13. Volume depletion (E869) | 95,031 (2.1) | Disc disorders with radiculopathy (M511) | 113,217 (2.3) | Sprain and strain of unspecified parts of knee (S836) | 163,976 (3.4) |
| 14. Fracture of neck of femur (S720) | 94,372 (2.0) | Asthma, unspecified (J459) | 106,652 (2.1) | Concussion (S060) | 162,564 (3.4) |
| 15. Calculus of gallbladder, no cholecystitis (K802) | 87,351 (1.9) | Hyperplasia of prostate (N409) | 106,459 (2.1) | Injury of conjunctiva and corneal abrasion (S050) | 155,675 (3.2) |
| 16. Spontaneous breech delivery (O802) | 86,451 (1.9) | Atrial fibrillation and flutter (I489) | 105,710 (2.1) | Open wound of eyelid and periocular area (S011) | 150,449 (3.1) |
| 17. Acute myocardial infarction, unspecified (I219) | 84,800 (1.8) | Unspecified hematuria (R319) | 105,548 (2.1) | Contusion of thorax (S202) | 149,719 (3.1) |
| 18. Cerebral infarction, unspecified (I639) | 84,001 (1.8) | Internal derangement of knee, unspecified (M239) | 104,986 (2.1) | Contusion of elbow (S500) | 147,950 (3.1) |
| 19. Complete or unspecified medical abortion (O049) | 80,284 (1.7) | Carpal tunnel syndrome (G560) | 96,247 (1.9) | Contusion of toe(s) without damage to nail (S901) | 133,673 (2.8) |
| 20. Heart failure, unspecified (I509) | 79,877 (1.7) | Calculus of gallbladder, no cholecystitis (K802) | 94,599 (1.9) | Sprain and strain of wrist (S635) | 133,174 (2.8) |
| 21. Acute appendicitis, unspecified (K359) | 74,769 (1.6) | Impingement syndrome of shoulder (M754) | 91,306 (1.8) | Superficial injury of head, part unspecified (S009) | 117,495 (2.5) |
| 22. Constipation (K590) | 73,162 (1.6) | COPD, unspecified (J449) | 89,555 (1.8) | Superficial injury of scalp (S000) | 117,118 (2.4) |
| 23. Acute cystitis (N300) | 72,768 (1.6) | Other primary gonarthrosis (M171) | 89,528 (1.8) | Open wound of other parts of wrist and hand (S618) | 116,600 (2.4) |
| 24. Vacuum extractor delivery (O814) | 69,842 (1.5) | Pain in limb (M796) | 86,225 (1.7) | Foreign body in cornea (T150) | 115,715 (2.4) |
| 25. Essential hypertension (I109) | 68,799 (1.5) | Low back pain (M545) | 85,920 (1.7) | Sprain and strain of cervical spine (S134) | 114,419 (2.4) |
Notes:
Both primary and secondary diagnoses are included. Factors influencing health status and contact with health services (Z-codes) are not included.
Abbreviation: ICD, International Classification of Diseases; COPD, chronic obstructive pulmonary disease.
Figure 2User interface of the Danish Health Care Classification System (SKS browser).
Notes: Available at http://www.medinfo.dk/sks/brows.php. English translation (consecutive line order): administrative data/classifications of treatment and care/classification of diseases/classifications of external causes of injury/International Classification of Functioning (ICF)/classification of surgery/Anatomical Therapeutic Chemical (ATC) classification system/anesthesia, intensive care, prehospital care/classification of examinations/temporary classification of examinations/specifications/supplementary codes/ZZ-procedure codes/ZZK, ZZP, ZZV, and ZPP codes and pseudo procedure codes (cancer, cancelled, discontinued)/classification of hospitals and departments.
Abbreviation: SKS, Sundhedsvæsenets Klassifikations System.
Summary results from the Danish Health and Medicines Authority’s evaluation of diagnoses in the Danish National Patient Registry in 1990 according to clinical specialties
| Clinical specialty | Positive predictive value of correct primary diagnoses
| |||
|---|---|---|---|---|
| Five-digit diagnosis codes
| Three-digit diagnosis codes
| |||
| Primary diagnosis alone (%) | Primary + two secondary diagnoses (%) | Primary diagnosis alone (%) | Primary + two secondary diagnoses (%) | |
| Medicine | 66 | 72 | 73 | 81 |
| Pediatrics | 74 | 80 | 82 | 89 |
| General surgery | 77 | 82 | 84 | 89 |
| Gynecology/obstetrics | 77 | 88 | 83 | 94 |
| Orthopedic surgery | 83 | 85 | 89 | 91 |
| Overall | 73 | 80 | 81 | 88 |
Use of the Danish National Patient Registry according to study design
| Cohort studies | Identifying study cohorts from hospitalized patients, the general population (assessed from registries or in combination with primary data collection), and family cohorts (constructed through linkage to the Danish Civil Registration System) |
| Identifying study exposures related to diseases, treatments, examinations, and seasonality | |
| Identifying disease occurrence in the general population (eg, associated with lifestyle factors identified from health surveys) or family cohorts | |
| Identifying disease outcome (recurrence or complications) in patients identified from the DNPR itself, clinical registries, or randomized trials | |
| Identifying health care utilization rates through counting frequency of inpatient/outpatient and planned/unplanned contacts | |
| Identifying temporal trends in disease incidence and use of treatments and diagnostic procedures | |
| Case–control studies | Identifying cases (and exposure from the DNPR, other registries, health surveys, or primary data collection). Risk-set sampling is possible through linkage to the Danish Civil Registration System |
| Cross-sectional studies | Identifying patient’s medical history at study entry according to diagnoses (index disease and comorbidities), treatments (in-hospital medical treatment, surgical procedures, anesthesia, and intensive care), and diagnostic procedures |
| Ecological studies | Identifying variations in health care and outcomes at the population level |
Abbreviation: DNPR, Danish National Patient Registry.
Figure 3Timeline for the initiation of selected Danish registries linkable to the Danish National Patient Registry.
Abbreviations: ADHD, attention deficit hyperactivity disorder; ICD, International Classification of Diseases; GP, general practitioner; COPD, chronic obstructive pulmonary disease.
Methodological considerations related to the internal validity of cohort studies conducted with data from the Danish National Patient Registry
| Precision | The large nationwide sample permits studies of rare diseases, disease complications, and treatment effects in subgroups of patients |
| Selection bias | The population-based coverage, within a universal health care system with virtually complete follow-up of all patients owing to the Danish Civil Registration System, reduces the risk of selection biases |
| Information bias | The risk of misclassification warrants validation of all variables used for research |
| Confounding | The registrations of diagnoses, treatments, and examinations for all hospital contacts may provide data on potential confounding factors. Seasonality may be controlled in the studies of infectious disease |
Bibliography of validated administrative data, diagnoses, treatments, and examinations in the Danish National Patient Registry
| ICD codes | Condition | Study period (contact type; diagnosis type) | ICD codes/algorithm | n | PPV; NPV; sensitivity; specificity | Reference standard | Reference |
|---|---|---|---|---|---|---|---|
| Acute medical admission | 2009 (IN) | Acute | 127 | PPV =97.6 (93.3–99.2); NPV =90.3 (75.1–96.7); Se =97.6 (93.3–99.2); Sp =90.3 (75.1–96.7) | MR | Vest-Hansen B et al. Clin Epidemiol. 2013 | |
| Nonacute medical admission | 2009 (IN) | Nonacute | 31 | PPV =90.3 (75.1–96.7); NPV =97.6 (93.3–99.2); Se =90.3 (75.1–96.7); Sp =97.6 (93.3–99.2) | MR | Vest-Hansen B et al. Clin Epidemiol. 2013 | |
| A00–B99: Certain infectious and parasitic diseases | |||||||
| A02 | Infections among patients diagnosed with cancer within previous 5 y (excl non-melanoma skin cancer) | 2006–2010 (IN; A) | A02.1, A02.2C, A15–A19, A20.3, A22.7, A26.7, A42.7, A28.2B, A31, A32.1, A32.7, A39.0, A40–41, A46, A49.9, A54.8D, A54.8G, A87, B00.3, B01.0, B02.1, B26.1, B35–B49, B05.1, G00–G05, H01.0, H03, H60.0, H60.1–H60.3, H62, I33, I39.8, J12–J18, K12.2, K13.0, K61, L01, L03, L08, M00, M01.1, M01.3, M72.6, M86, N10–N12, N15.1, N15.9, N30, N34, N39.0 | 266 | PPV =98.1 (95.7–99.2) overall, 80.1 (75.0–84.5) for agreement of specific infection type, 79.0 (63.7–88.9) for skin infection, 92.5 (85.3–96.3) for pneumonia, 84.4 (71.2–92.3) for sepsis | MR | Holland-Bill L et al. Ann Epidemiol. 2014 |
| A39 | Meningococcal disease | 1980–1993 (IN; A/B | 036.09, 036.10, 036.11, 036.12, 036.18, 036.19, 036.89, 036.99 | 296 | PPV =85.8 (81.4–89.3); Se =89.8 (85.7–92.8) | MR (ref for PPV); Notification system for communicable diseases and DNPR (ref for Se) | Sørensen HT et al. Int J Risk Saf Med. 1995 |
| A40 | Septicemia | 1994 (IN; A/B | A02.1, A28.2, A40–41, A42.7, A54.8, O08.0, O75.3, O85.9, P36 | 83 | PPV =21.7 (14.2–31.7); Se =4.4 (2.8–6.9) | MR; Bacteremia database | Madsen KM et al. Infect Control Hosp Epidemiol. 1998 |
| Bacteremia | 2000–2011 (IN; A/B | Definite (A02.1, A28.2B, A32.7, A39.2–4, A40–1, A42.7, A49.9A, B37.7, B49.9A) or possible (predominantly, A01.0, A39.0, A41.9, A46.9, I38.9, P36, P37.5, N10.9, N30.0, N39.0, O08.0U, O08.0V, KTJA40, KTJWC00, KTJL10) | 37,740 | SeDefinite/possible =64.9 (64.5–65.3) | Microbiology results recorded in electronic laboratory information system | Gradel KO et al. Plos One. 2015 | |
| A41 | Gram-negative bacteremia | 1994–2012 (IN; A/B) | A41.5, A41.9B (septicemia/sepsis due to other Gram-negative organisms or urosepsis) | 100 | PPVAll =72.0 (62.5–79.9); PPVA41.5 =85.7 (74.3–92.6); PPVA41.9B =54.6 (40.1–68.3) | Microbiology results recorded in electronic laboratory information system | Søgaard KK et al. Clin Epidemiol. 2014 |
| B18.0 | HBV in HIV patients | 1995–2004 (IN/OUT; A/B | B18.0–B18.1 | 47 | PPV =63.8 (49.5–76.0); Se =23.3 (16.8–31.3) | Danish HIV Cohort Study | Obel N et al. BMC Med Res Methodol. 2008 |
| B18.2 | HCV in HIV patients | 1995–2004 (IN/OUT; A/B | B18.2 | 134 | PPV =94.0 (88.7–96.9); Se =47.7 (41.8–53.7) | Danish HIV Cohort Study | Obel N et al. BMC Med Res Methodol. 2008 |
| B20 | HIV | 1995–2004 (IN/OUT; A/B | B20–B24 | n/a (≥2006) | Se =98.7 (98.1–99.1) | Danish HIV Cohort Study | Obel N et al. BMC Med Res Methodol. 2008 |
| B21 | AIDS | 1998–2007 (IN/OUT; A) | B21–B24 | 50 | PPV =100 (92.9–100) | DS | Thygesen SK et al. BMC Med Res Methodol. 2011 |
| C00–D48: Neoplasms | |||||||
| C00–C75 | Any tumor | 1998–2007 (IN/OUT; A) | C00–C75 | 50 | PPV =98.0 (89.4–99.9) | DS | Thygesen SK et al. BMC Med Res Methodol. 2011 |
| 1977 (IN; A/B) | 140–239 (excl brain tumors and non-melanoma skin cancer) | 17,956 | PPV =91.7 (91.3–92.1); Se =75.8 (75.2–76.3) | DCR | Osterlind A et al. Ugeskr Laeger. 1985 | ||
| C18 | Colorectal cancer | 2001–2006 (IN/OUT; | C18–20 | 24,153 | PPV =88.9 (88.5–89.3); Se =93.4 (93.1–93.7) | DCR | Helqvist L et al. Eur J Cancer Care. 2012 |
| Colorectal cancer recurrences | 2001–2011 (IN/OUT/ED; | C76–C80, C18.9X, C20.9X, BWHA1–2, BOHJ17, BOHJ19B1 (algorithm combining metastasis and chemotherapy codes in the DNPR with cancer recurrence codes in the PD) | 70 | PPV =85.7 (75.7–92.1); NPV =99.0 (97.0–100); Se =95.2 (86.9–98.4); Sp =96.6 (93.8–98.1) | Actively followed cohort | Lash TL et al. Int J Cancer. 2014 | |
| C51–58 | Gynecological cancers | 1977–1988 (IN; A/B | 180, 182.0, 183 (among women undergoing gynecological surgery) | 614 | PPV =89.9 (87.3–92.0); Se =94.7 (92.6–96.2) | MR | Kjaergaard J et al. J Epidemiol Biostat. 2001 |
| C53 | Cervical cancer | 1977–1988 (IN; A/B | 180 (among women undergoing gynecological surgery) | 148 | PPV =88.5 (82.4–92.7); Se =94.2 (89.1–97.1) | MR | Kjaergaard J et al. J Epidemiol Biostat. 2001 |
| C54–55 | Uterus cancer | 1977–1988 (IN; A/B | 182.00–182.09 (among women undergoing gynecological surgery) | 261 | PPV =90.4 (86.2–93.4); Se =92.9 (89.1–95.5) | MR | Kjaergaard J et al. J Epidemiol Biostat. 2001 |
| C56 | Ovarian cancer | 1977–1988 (IN; A/B | 183 | 205 | PPV =90.2 (85.4–93.6); Se =97.4 (94.0–98.9) | MR | Kjaergaard J et al. J Epidemiol Biostat. 2001 |
| C61 | Prostate cancer | 1995–2012 (IN/OUT; A/B) | C61 | 240 | PPV =98.3 (95.8–99.4) | MR (histologically-/biopsy-verified) | Drljevic A et al. Clin Epidemiol 2014 |
| C64 | Urological cancer | 2004–2009 (IN/OUT; A/B | C64–68, D09.0–D09.1, D30.1–D30.9, D41.1–D41.9 | 41,129 | PPV =86.6 (86.3–86.9); Se =94.9 (94.7–95.2) | DCR | Gammelager H et al. Eur J Cancer Prev 2012 |
| C76–80 | Metastatic solid tumor | 1998–2007 (IN/OUT; A) | C76–C80 | 50 | PPV =100 (92.9–100) | DS | Thygesen SK et al. BMC Med Res Methodol. 2011 |
| C79.5 | Bone metastases or skeletal-related events in patients with prostate (P) or breast (B) cancer | 2000–2005 (n/a; n/a) | C79.5, BWGC1, M80.0, M84.4, M90.7, M43.9, 48.5, M54.5, M54.6, M54.9, G95.2, G95.8, KNAG (+ C61.9/C50) | 27 P; 15 B | PPVP =92.6 (76.6–97.9); NPVP =71.2 (60.0–80.4); PPVB =73.3 (48.1–89.1); NPVB =90.6 (82.5–95.2); SeP =54.4 (40.2–67.9); SpP =96.3 (87.5–99.0); SeB =57.9 (36.3–76.9); SpB =95.1 (88.0–98.1) | MR | Jensen AØ et al. Clin Epidemiol. 2009 |
| C79.5 | Bone metastases in patients with prostate cancer | 2005–2010 (IN/OUT; | C61 (from DCR) with prespecified PSA values, antiresorptive therapy, and bone scintigraphy, but without C77–C79 | 212 | PPVPSA >50 μg/L =9.6 (4.7–18.5) and NPVPSA <50 μg/L =98.6 (94.9–99.6) regardless of receipt of antiresorptive therapy or presence of bone scintigraphy | MR | Ehrenstein V et al. Clin Epidemiol. 2015 |
| C81.0–96.9 | Hematological cancer | 1994–1999 (IN; | C81.0–C96.9 | 1,075 | PPV =84.5 (82.2–86.5); Se =91.5 (89.6–93.1) | DCR | Nørgaard M et al. Eur J Cancer Prev. 2005 |
| C81 | Lymphoma | 1998–2007 (IN/OUT; A) | C81–C85, C88, C90, C96 | 50 | PPV =100 (92.9–100) | DS | Thygesen SK et al. BMC Med Res Methodol. 2011 |
| C81 | Hodgkin’s disease | 1994–1999 (IN; | C81.0–9 | 77 | PPV =71.4 (60.5–80.3); Se =88.7 (78.5–94.4) | DCR | Nørgaard M et al. Eur J Cancer Prev. 2005 |
| C82 | Non-Hodgkin’s lymphoma or chronic lymphocytic leukemia | 1994–1999 (IN; | C82.0–85.9, C88.0–9, C91.1, C96.0–9 | 613 | PPV =85.3 (82.3–87.9); Se =88.2 (85.3–90.6) | DCR | Nørgaard M et al. Eur J Cancer Prev. 2005 |
| C90 | Multiple myeloma and other malignant plasma cell neoplasms | 1994–1999 (IN; | C90.0–2 | 158 | PPV =82.3 (75.6–87.4); Se =90.9 (85.1–94.6) | DCR | Nørgaard M et al. Eur J Cancer Prev. 2005 |
| C91 | Leukemia | 1998–2007 (IN/OUT; A) | C91–C95 | 50 | PPV =100 (92.9–100) | DS | Thygesen SK et al. BMC Med Res Methodol. 2011 |
| C92 | Acute myeloid leukemia | 1994–1999 (IN; | C92.0 | 108 | PPV =67.6 (58.3–75.7); Se =89.0 (80.4–94.1) | DCR | Nørgaard M et al. Eur J Cancer Prev. 2005 |
| D25 | Uterine fibroma | 1977–1988 (IN; A/B) | 218.99 (among women undergoing gynecological surgery) | 1,430 | PPV =92.9 (91.4–94.1); NPV =88.9 (87.8–89.9); Se =77.4 (75.4–79.4); Sp =96.8 (96.2–97.4) | DS | Kjaergaard J et al. J Clin Epidemiol. 2002 |
| D27 | Benign ovarian neoplasms | 1977–1988 (IN; A/B) | 220.99 (among women undergoing gynecological surgery) | 743 | PPV =78.2 (75.1–81.0); NPV =90.0 (89.1–90.9); Se =58.3 (55.2–61.3); Sp =95.9 (95.2–96.5) | DS | Kjaergaard J et al. J Clin Epidemiol. 2002 |
| D35.3 | Craniopharyngioma | 1985–2004 (IN/OUT; | 194.39, 226.21, 226.29, 253.99; D35.3, D44.4, C75.2 | 607 | PPV =30.5 (27.0–34.3); Se =95.2 (77.3–99.2) | MR (for PPV)/Se with ref to North Jutland County registry and registries of a Danish neuroendocrine center | Nielsen EH et al. J Clin Epidemiol. 2011 |
| D47.2 | Monoclonal gammopathy | 2001–2011 (IN/OUT; | D47.2 | 327 | PPV =82.3 (77.8–86.0); Se =16.8 (14.4–19.6) | MR (for PPV); Se with ref to Regional monoclonal gammopathy database | Gregersen H et al. Clin Epidemiol. 2013 |
| D50–D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | |||||||
| D35.0A | Pheochromocytoma | 1977–1981 (IN; A/B) | 255.29 | 230 | PPV =19.1 (14.6–24.7) | MR | Andersen GS et al. Ugeskr Laeger. 1986 |
| D50.0 | Anemia caused by bleeding | 2000–2009 (IN/OUT; A/B | D50.0, D62.6 | 3,391 | PPV =95.4 (94.6–96.0) | LABKA | Zalfani J et al. Clin Epidemiol. 2012 |
| D51 | Anemia caused by B12 deficiency | 2000–2009 (IN/OUT; A/B | D51 | 1,089 | PPV =36.8 (34.0–39.7) | LABKA | Ghezala IB et al. Clin Epidemiol. 2012 |
| D69 | Chronic idiopathic thrombocytopenic purpura | 1996–2007 (IN/OUT; | D69 (>1 diagnosis >6 mo) | 439 | PPV =93.4 (90.7–95.4) | MR | Heden KEK et al. Clin Epidemiol. 2009 |
| E00–E90: Endocrine, nutritional and metabolic diseases | |||||||
| E10 | Diabetes mellitus | 1998–2007 (IN/OUT; A) | E10.0, E10.1, E10.9, E11.0, E11.1, E11.9 | 50 | PPV =96.0 (86.5–98.9) | DS | Thygesen SK et al. BMC Med Res Methodol. 2011 |
| 1999–2003 (IN/OUT; | E10–13, H36.0, O24, except O24.4 | n/a | PPV =64; | GP verification | Kristensen JK et al. Ugeskr Laeger. 2007 | ||
| 1992–2001 (IN/OUT/ED; | 249–250, E10–E11 (and/or a prescription for insulin or an oral antidiabetes drug) | 65 | PPV =96.9 (89.5–99.2) | MR, LABKA | Thomsen RW et al. Diabetes Care. 2004 | ||
| Diabetes in women | 1977–2006 | 249; E10 | 40 | PPV =95.0 (83.5–98.6) | MR | Atladottir HO et al. Pediatrics. 2009 | |
| Diabetes in children | 1996–2002 (A; | E10–14 (age ≤15 y) | 1,479 | PPV =95.9 (94.8–96.8); NPV =100 (100–100); | MR; Danish registry for child and adolescent diabetes | Svensson J et al. Ugeskr laeger. 2007 | |
| Type 1 diabetes mellitus | 1996–2002 (IN; | E10–14 | 1,479 | PPV =94.3 (93.0–95.4); NPV =100 (100–100); | MR; Danish registry for child and adolescent diabetes | Svensson J et al. Ugeskr laeger. 2007 | |
| 1987–1993 (IN; A/B) | 249 | 1,722 | PPV =96.3 (95.4–97.1); Se =91.0 (89.6–92.2) | MR; PR | Nielsen GL et al. J Med Syst. 1996 | ||
| E10.2 | Diabetes mellitus with chronic complications | 1998–2007 (IN/OUT; A) | E10.2–E10.8, E11.2–E11.8 | 50 | PPV =82.0 (69.2–90.2) | DS | Thygesen SK et al. BMC Med Res Methodol. 2011 |
| E22.0 | Acromegaly | 1991–2009 (IN/OUT/ED; | 253.00, 253.01; E22.0 | 275 | PPV =54.2 (48.3–60.0); PPVDep of endocrinology =66.7 (60.0–72.7) | MR | Dal J et al. Clin Epidemiol. 2014 |
| E282 | Polycystic ovarian syndrome | 1977–1988 (IN; A/B) | 256.90 (among women undergoing gynecological surgery) | 14 | PPV =85.7 (60.1–96.0); NPV =99.9 (99.8–100); Se =70.6 (46.9–86.7); Sp =100 (99.9–100) | DS | Kjaergaard J et al. J Clin Epidemiol. 2002 |
| E26.0 | Primary hyperaldosteronism | 1977–1981 (IN; A/B) | 255.00 (Conn’s syndrome) | 85 | PPV =22.4 (14.8–32.3) | MR | Lund JO et al. Ugeskr Laeger. 1986 |
| E41 | Undernutrition | 2002–2011 (IN; | E12, E41–44, E46–47, E64, Z03.8F (age ≥15 y) | 172 | PPVDefinite =11.1 (7.2–16.6) | MR | Rasmussen NH et al. |
| E87 | Hyponatremia | 2006–2011 (IN; A/B) | E87.1, E87.1A, P74.2B | 5,850 | PPV =92.5 (91.8–93.1); NPV =86.2 (86.2–86.2); Se =1.8 (1.7–1.8); Sp =100 (100–100) | LABKA | Holland-Bill L et al. BMJ Open. 2014 |
| F00–F99: Mental and behavioral disorders | |||||||
| F00 | Dementia | 1998–2007 (IN/OUT; A) | F00–F03, F05.1, G30 | 50 | PPV =98.0 (89.5–99.7) | DS | Thygesen SK et al. BMC Med Res Methodol. 2011 |
| 2003 (IN/OUT; A/B) | F00.0–F00.2, F00.9, G30.0–G30.1, G30.8–G30.9, F01.0–F01.3, F01.8–F01.9, F02.0, F03.9 | 197 | PPV =85.8 (80.2–90.0) overall, 81.0 (69.2–89.1) for Alzheimer dementia, 18.5 (8.2–36.7) for vascular dementia | MR; patient interview | Phung TKT et al. Dement Geriatr Cogn Disord. 2007 | ||
| G00–G99: Diseases of the nervous system | |||||||
| G12.2 | Amyotrophic lateral sclerosis | 1982–2009 (IN/OUT; | 348.0, G12.2 (age >19 y) | 173 | PPVdefinite =69.9 (62.7–76.3); PPVdefinite/probable =77.5 (70.7–83.1); PPVdefinite/probable/suspected =92.5 (87.6–95.6) | MR | Kioumourtzoglou MA et al. Amyotroph Lateral Scler Frontotemporal Degener. 2015 |
| G20 | Parkinson’s disease | 1996–2006 (IN/OUT; A) | 342, G20 | 1,040 | PPV =82.4 (80.0–84.6) | MR | Wermuth L et al. Dan Med J 2012 |
| 2002–2006 (IN/OUT; | G20 (age ≥35 y) | 2,572 | PPV =91.5 (90.3–92.5) | PR | Rugbjerg K et al. BMJ. 2008 | ||
| Parkinson’s disease (women) | 1996–2009 (IN/OUT; | G20 | 923 | PPV =80.5 (77.8–82.9) | MR | Greene N et al. Eur J Neurol. 2014 | |
| G35.9 | Multiple sclerosis treated at Department of Neurology or MS rehabilitation center | 1994–2004 (IN/OUT; A/B) | G35.9 | 4,185 | PPV =95.1 (94.3–95.8); | Danish Multiple Sclerosis Registry | Mason K et al. Acta Neurol Scand. 2012 |
| G40 | Epilepsy | 1977–2002 (IN/OUT; A/B | 345, G40–41 | 188 | PPV =81.4 (75.2–86.3) | MR | Christensen J et al. Epilepsy Res. 2007 |
| G45 | Transient ischemic attack | 1998–1999 (IN; | G45 | 38 | PPV =57.9 (42.2–72.2) to 68.4 (52.5–80.9) | MR; DS; CT/MRI; autopsy reports; angiography reports | Krarup LH. Neuroepidemiology. 2007 |
| 1994–1999 | G45 | 134 | PPV =60.5 (52.0–68.3) | MR; DS | Johnsen SP et al. J Clin Epidemiol. 2002 | ||
| G81 | Hemiplegia | 1998–2007 (IN/OUT; A) | G81, G82 | 50 | PPV =100 (92.9–100) | DS | Thygesen SK et al. BMC Med Res Methodol. 2011 |
| H00–H95: Diseases of the eye, adnexa, ear, and mastoid process | |||||||
| H71 | Cholesteatoma | 1977–2007 (IN; A) | 387.09; H71, H95.0, Q16.4A + surgery codes (see these below under KDC) | 262 | PPV =89.3 (85.0–92.5); Se =89.3 (84.7–92.6) | Surgical records | Djurhuus BD et al. Dan Med Bull. 2010 |
| I00–I99: Diseases of the circulatory system | |||||||
| I10.9 | Essential hypertension in males | 1977–2010 (IN/OUT; A/B) | 400–404; I10–I15 | 524 | PPV =88.2 (85.4–90.9) | PR | Schmidt M et al. BMJ Open. 2013 |
| Essential hypertension | 1983–1990 (IN; A) | 401.99 | 310 | PPV =40 (26–55) to 60 (49–70) | MR | Nielsen HW et al. Ugeskr Læger. 1996 | |
| I20.0 | Acute coronary syndrome | 1993–2003 (IN/OUT/ED; A/B | 410, 427.27; I20.0, I21, I46 | 1,558 | PPVIN/OUT/ED =65.5 (63.1–67.9); PPVIN =80.1 (77.7–82.3) | MR; DS; blood tests, ECG | Joensen AM et al. J Clin Epidemiol. 2009 |
| I20.0 | Unstable angina | 1993–2003 (IN/OUT/ED; A/B | I20.0 | 444 | PPVIN/OUT/ED =27.5 (23.5–31.8); PPVIN =42.0 (36.0–48.0) | MR; DS; blood tests, ECG | Joensen AM et al. J Clin Epidemiol. 2009 |
| I21 | Acute myocardial infarction | 1996–2009 (IN; | I21 | 148 | PPV =100 (97.5–100) | MR | Coloma PM et al. BMJ Open. 2013 |
| 1998–2007 (IN/OUT; A) | I21, I22, I23 | 50 | PPV =98.0 (89.5–99.7) | DS | Thygesen SK et al. BMC Med Res Methodol. 2011 | ||
| 1993–2003 (IN/OUT/ED; A/B | 410; I21 | 1,072 | PPVIN/OUT/ED =81.9 (79.5–84.1); PPVIN; A/B =92.4 (90.4–93.9); PPVIN; A =94.4 (92.6–95.7) | MR; DS; blood tests, ECG | Joensen AM et al. J Clin Epidemiol. 2009 | ||
| 1982–1991 (IN; A/B) | 410, 427.24, 427.27, 427.91, 427.97 | 5,022 | PPVA =94.3 (93.6–94.9); PPVA+B =93.4 (92.6–94.0); SeA =62.8 (61.7–64.0); SeA+B =69.5 (68.4–70.6) | DANMONICA definite or possible cases incl cardiac arrest | Madsen M et al. J Clin Epidemiol. 2003 | ||
| 1979–1980 (IN; A/B) | 410–414 | 527 | PPV =92.4 (89.8–94.4) | DS | Madsen M et al. Ugeskr laeger. 1990 | ||
| I26 | PE | 1994–2006 (IN/OUT/ED; A/B) | 450.99; I26 | 353 | PPVAll =67.4 (62.4–72.1); PPVIN/OUT =82.1 (77.2–86.1); PPVED =29.6 (22.0–38.5); PPVA =87.0 (81.9–90.9) | MR; DS; blood tests; ultrasound; venography; echo; V-P lung scan; CT scan | Severinsen MT et al. J Clin Epidemiol. 2010 |
| PE during pregnancy and postpartum | 1980–2001 (IN; | 450.00–450.99; I26.0–I26.9 + (650–666; O80–84) | 22 | PPVpreg+postpartum =81.8 (59.7–94.8); | MR | Larsen TB et al. J Clin Epidemiol. 2005 | |
| PE after stroke | 2003–2006 (IN; A/B) | I26 (after admission to stroke units and age ≥18 y) | 11 | PPV =90.9 (62.3–98.4); NPV =97.4 (95.8–98.4); Se =0.0 (0.0–32–4); Sp =100 (99.3–100) | MR | Ingeman A et al. Clin Epidemiol. 2010 | |
| I46 | Cardiac arrest | 1993–2003 (IN/OUT/ED; A/B | 427.27; I46 | 42 | PPVIN/OUT/ED =50.0 (35.5–64.5); PPVIN =53.1 (36.5–69.1) | MR; DS; blood tests, ECG | Joensen AM et al. J Clin Epidemiol. 2009 |
| I48 | Atrial fibrillation or flutter | 1993–2009 (IN/OUT/ED; A/B) | 427.93, 427.94; I48 | 284 | PPVAll =92.3 (88.6–94.8); PPVIN/OUT =94.0 (90.5–96.3) (independent of diagnosis type and department specialty); PPVED =64.7 (41.3–82.7) | MR + heart rhythm documentation | Rix TA et al. Scand Cardiovasc J. 2012 |
| 1980–2002 (n/a; n/a) | 427.93, 427.94; I48 | 174 | PPV =98.9 (95.9–99.7) | MR + heart rhythm documentation | Frost L et al. Am J Med. 2007 | ||
| 1980–2002 (n/a; n/a) | 427.93, 427.94; I48 | 116 | PPV =96.6 (91.5–98.7) | MR + heart rhythm documentation | Frost L et al. Arch Intern Med. 2004 | ||
| I48.9A | Atrial flutter | 1977–1999 (IN/OUT/ED; A/B) | 427.94; I48.9A | 108 | PPV =50.0 (40.7–59.3) | MR + heart rhythm documentation | Rix TA et al. Scand Cardiovasc J. 2012 |
| I50 | Heart failure | 1998–2007 (IN/OUT; A) | I50, I11.0, I13.0, I13.2 | 50 | PPV =100 (92.9–100) | DS | Thygesen SK et al. BMC Med Res Methodol. 2011 |
| Heart failure at University Hospital cardiac care unit | 2005–2007 (IN/OUT; A/B) | I11.0, I13.0, I13.2, I42.0, I42.6–9, I50.0–I50.1, I50.9 | 758 | PPVOverall = 84.0 (81.3–86.5); PPFirst-time events = 77.9 (74.1–81.6) | MR | Mard S et al. Clin Epidemiol. 2010 | |
| 1998–1999 (IN; A/B) | I50 | 156 | PPV =80.8 (73.9–86.2); NPV =90.1 (88.9–91.2); Sp =98.9 (98.5–99.2); Se =29.4 (25.3–33.9) | Clinical examination | Kümler T et al. Eur J Heart Fail. 2008 | ||
| I60–I69 | Cerebrovascular disease | 1998–2007 (IN/OUT; A) | I60–I69, G45–G46 | 50 | PPV =94.0 (83.8–97.9) | DS | Thygesen SK et al. BMC Med Res Methodol. 2011 |
| 1998–1999 (IN; | I60–I69, G45 | 236 | PPV =78.4 (72.7–83.2) to 80.1 (74.5–84.7) | MR; DS | Krarup LH et al. Neuroepidemiology. 2007 | ||
| 1994–1999 | I60–I69.8, G45 | 565 | PPV =68.5 (64.6–72.2) | MR; DS | Johnsen SP et al. J Clin Epidemiol. 2002 | ||
| I60–I64 | Stroke | 1980–2002 (n/a; A/B) | 430–434, 436; I60–I64 following a diagnosis of atrial fibrillation/flutter | 164 | PPV =97.0 (93.1–98.7) | MR | Frost L et al. Am J Med. 2007 |
| 2010 (IN; A) | I61, I63–I64 admitted to neurologic wards | 46 | PPV =93.5 (82.5–97.8); NPV =71.8 (62.8–79.4); Se =58.1 (46.7–68.7); Sp =96.3 (89.8–98.8) | MR including MRI and CT scan (for PPV). Other neurologic disorders were included to assess Se, Sp, and NPV | Wildenschild K et al. Clin Epidemiol. 2013 | ||
| 1998–1999 (IN; | I60–I64 | 164 | PPV =80.5 (73.8–85.8) to 86.0 (79.8–90.5) | MR; DS | Krarup LH et al. Neuroepidemiology. 2007 | ||
| 1994–1999 | I60–I64 | 377 | PPV =79.3 (74.9–83.1) | MR; DS | Johnsen SP et al. J Clin Epidemiol. 2002 | ||
| Stroke complications | 2003–2006 (IN; A/B) | J12–J18, N30.0, N30.8, N30.9, N10, L899, R297, EUHE, I82.9A-E, I26, K590 (after admission to stroke units and age ≥18 y) | 88 | PPV =76.1 (66.3–83.8); NPV =85.1 (83.9–86.1); Se =7.7 (5.8–10.3); Sp =99.5 (99.2–99.7) | MR | Ingeman A et al. Clin Epidemiol. 2010 | |
| I60 | Subarachnoid hemorrhage | 1998–1999 (IN; | I61 | 3 | PPV =66.7 (20.8–93.9) | MR; DS | Krarup LH et al. Neuroepidemiology. 2007 |
| 1994–1999 | I61 | 29 | PPV =48.3 (31.4–65.6) | MR; DS | Johnsen SP et al. J Clin Epidemiol. 2002 | ||
| 1977–1995 (IN; | 430; I60 | 191 | PPVneurosurgery wards =93 (85–98); | MR; DS; autopsy reports | Gaist D et al. BMJ. 2000 | ||
| I6I | Intracerebral hemorrhage | 1998–1999 (IN; | I60 | 23 | PPV =73.9 (53.5–87.5) | MR; DS | Krarup LH et al. Neuroepidemiology. 2007 |
| 1994–1999 | I60 | 35 | PPV =65.7 (49.2–79.2) | MR; DS | Johnsen SP et al. J Clin Epidemiol. 2002 | ||
| I63 | Ischemic stroke | 1998–1999 (IN; | I63 | 33 | PPV =97.0 (84.7–99.5) to 100 (89.6–100) | MR; DS | Krarup LH et al. Neuroepidemiology. 2007 |
| 1994–1999 | I63 | 113 | PPV =87.6 (80.3–92.5) | MR; DS | Johnsen SP et al. J Clin Epidemiol. 2002 | ||
| Pediatric arterial thrombosis (0–18 y) | 1994–2006 (IN/OUT/ED; | I63–I64, H34.1–H34.2, I74, N28.0A, N28.0D, I21 | 472 | PPVall =53.6 (49.1–58.1); PPVED =7.3 (2.5–19.4); PPVward =58.0 (53.3–62.6); PPVneonates =75.3 (64.9–83.4) | MR; lab tests; ECG; radiology reports | Tuckuviene R et al. Clin Epidemiol. 2010 | |
| I64 | Unspecified stroke | 1998–1999 (IN; | I64 | 105 | PPV =72.4 (63.2–80.0) to 80.0 (71.4–86.5) for unspecified stroke confirmed as being any stroke | MR; DS | Krarup LH et al. Neuroepidemiology. 2007 |
| 1994–1999 | I64 | 200 | PPV =76.0 (69.6–81.4) for unspecified stroke confirmed as being any stroke | MR; DS | Johnsen SP et al. J Clin Epidemiol. 2002 | ||
| I70 | Peripheral vascular disease | 1998–2007 (IN/OUT; A) | I70–I74, I77 | 50 | PPV =100 (92.9–100) | DS | Thygesen SK et al. BMC Med Res Methodol. 2011 |
| I80.0 | Superficial thrombophlebitis during pregnancy/d postpartum | 1980–2001 (IN; | 451.01, 451.91; I800 + (650–666; O80–84) | 125 | PPVpreg+postpartum =89.6 (84.3–95.0); | MR | Larsen TB et al. J Clin Epidemiol. 2005 |
| I80.1–3 | DVT | 1994–2006 (IN/OUT/ED; A/B) | 451.00, 451.08, 451.09, 451.99; I80.1–I80.9 | 742 | PPVAll =54.6 (51.0–58.1); PPVIN/OUT =71.3 (67.4–74.9); PPVED =31.9 (27.1–37.0); PPVA =72.4 (68.2–76.2) | MR; DS; blood tests; ultrasound; venography; echo; V-P lung scan; CT scan | Severinsen MT et al. J Clin Epidemiol. 2010 |
| DVT during pregnancy and postpartum | 1980–2001 (IN; | 451.00, 451.08–451.09, 451.90, 451.92, 451.99; I80.1–I80.9 + (650–666; O80–84) | 153 | PPVpreg+postpartum =86.3 (79.8–91.3); | MR | Larsen TB et al. J Clin Epidemiol. 2005 | |
| DVT after stroke | 2003–2006 (IN; A/B) | I82.9 (after admission to stroke units and age ≥18 y) | 8 | PPV =87.5 (52.9–97.8); NPV =97.1 (95.4–98.2); Se =16.7 (3.0–56.4); Sp =100 (99.3–100) | MR | Ingeman A et al. Clin Epidemiol. 2010 | |
| I80.1–3+ I26 | VTE | 1994–2006 (IN/OUT/ED; A/B) | 450.99, 451.00, 451.08, 451.09, 451.99; I26, I80.1–I80.9 | 1,100 | PPVAll =58.5 (55.5–61.3); PPVIN/OUT =75.0 (71.9–77.8); PPVED =31.3 (27.2–35.7); PPVA =77.0 (73.7–80.0) | MR; DS; blood tests; ultrasound; venography; echo; V-P lung scan; CT scan | Severinsen MT et al. J Clin Epidemiol. 2010 |
| 2004–2012 (IN/OUT; A/B) | I80.1–3, I26 + AC prescription ≤30 d after | 20 | PPV =90.0 (69.9–97.2) | MR | Schmidt M et al. J Thromb Haemost. 2014 | ||
| Pediatric VTE (0–18 y) | 1994–2006 (IN/OUT/ED; | I67.6, I63.6, G0.8, H34.8, I26, I80.1–I80.9, I81–I82, O22.5A, O87.3, O22.3, O22.8–O22.9, O87A–O87F, O87.1 | 640 | PPVall =53.9 (50.0–57.7); PPVED =7.4 (4.1–13.1); PPVward =66.3 (62.1–70.3); PPVneonates =82.4 (66.5–91.7) | MR | Tuckuviene R et al. Clin Epidemiol. 2010 | |
| VTE in non-pregnant women 15–49 y | 2001–2009 (IN/OUT; | 438, 450, 451.00, 451.08, 451.99, 453.02; I26, I67.6, I80.1–I80.3,I82.2–I82.3, I82.8–I82.9 | 200 | PPV =76.0 (69.6–81.4); PPV+AC =99 | MR; ultrasound; phlebography; CT; scintigraphy | Lidegaard O et al. BMJ. 2011 | |
| VTE during pregnancy and postpartum | 1980–2001 (IN; | 450.00–450.99, 451.00–451.99; I26.0–I26.9, I80.0–I80.9 + (650–666, O80–84) | 304 | PPVpreg+postpartum =87.3 (83.0–90.9); | MR | Larsen TB et al. J Clin Epidemiol. 2005 | |
| VTE recurrence | 2004–2012 (IN/OUT; A/B) | I80.1–3, I26 (>3 mo after first–time diagnosis) + ultrasound/CT scan during admission or AC prescription ≤30 d after | 90 | PPVIN/OUT, A/B, scan =27.5 (16.1–42.8); PPVIN/OUT, A/B, AC use =30.2 (18.6–45.1); PPVIN, A/B, scan =79.0 (56.7–91.5); PPVIN, A/B, AC use =56.5 (36.8–74.4) | MR | Schmidt M et al. J Thromb Haemost. 2014 | |
| VTE in prostate cancer patients | 1995–2012 (IN/OUT; A/B) | I26, I80.1–3 (+ C61) | 115 | PPV =86.1 (78.6–91.3); NPV =98.3 (94.0–99.5); Se =98.0 (93.1–99.5); Sp =87.8 (81.1–92.3) | MR; VTE diagnostics | Drljevic A et al. Clin Epidemiol 2014 | |
| J00–J99: Diseases of the respiratory system | |||||||
| J12 | Respiratory syncytial virus infections | 1996–2003 (IN; A/B) | J12.1, J20.5, J21.0, B97.4 | 10,983 | PPV =92.1 (91.5–92.6); NPV =83.8 (83.4–94.2); Se =67.9 (67.1–68.6); Sp =96.6 (96.4–96.8) | MR; RSV Laboratory database | Stensballe LG et al. Scand J Infect Dis. 2005 |
| J12 | Pneumonia after stroke | 2003–2006 (IN; A/B) | J12–J18 after (admission to stroke unit and age ≥18 y) | 14 | PPV =92.9 (68.5–98.7); NPV =63.3 (59.3–67.1); Se =6.0 (3.5–10.1); Sp =99.7 (98.5–100) | MR | Ingeman A et al. Clin Epidemiol. 2010 |
| J40 | Chronic pulmonary disease | 1998–2007 (IN/OUT; A) | J40–J47, J60–J67, J68.4, J70.1, J70.3, J84.1, J92.0, J96.1, J98.2, J98.3 | 50 | PPV =100 (92.9–100) | DS | Thygesen SK et al. BMC Med Res Methodol. 2011 |
| J44 | COPD exacerbation | 2008 (IN; A/B) | J44A, J96A, J13A–J18A + J44B (age ≥30 y) | 1,581 | PPV =92.1 (90.7–93.3); NPVCOPD for related respiratory conditions =80.6 (78.5–82.5) | MR; 1,546 acute hospitalizations for J96 or J13–18 without J44 as B-diagnosis used to obtain NPV | Thomsen RW et al. Respir Med. 2011 |
| J45 | Asthma history reported by male conscripts | 1977–2003 (IN/OUT/ED; A/B | 493; J45 | 925 | PPV =65.3 (62.2–68.3); NPV =96.5 (96.2–96.7); Se =44.5 (41.9–47.1); Sp =98.5 (98.3–98.6) | Conscription database | Jensen AO et al. Clin Epidemiol. 2010 |
| J45 | Asthma in children | 2002 (IN; A) | J45, J46.9 (age 6–14 y) | 319 | PPV =84.6 (80.3–88.2); NPV =99.4 (99.1–99.6); Se =90.0 (86.1–92.9); Sp =99.4 (99.1–99.6) | MR; All acute admissions were assessed to yield Se, Sp, and NPV | Moth G et al. Acta Paediatr. 2007 |
| J86.0 | Pleural empyema | 1995–2009 (IN; A/B) | 510; J86.0, J86.9 | 224 | PPV =90.6 (86.1–93.8) | MR; lab tests; radiology reports | Søgaard M et al. Clin Epidemiol 2011 |
| K00–K93: Diseases of the digestive system | |||||||
| K25 | Ulcer disease | 1998–2007 (IN/OUT; A) | K22.1, K25–K28 | 50 | PPV =98.0 (89.5–99.7) | DS | Thygesen SK et al. BMC Med Res Methodol. 2011 |
| 1997–2001 n/a; n/a) | 531–534, K25–K28 | 200 | PPVOverall =84.5 (78.8–88.7); PPVbleeding ulcer =93.0 (84.6–97.0); PPVuncomplicated ulcer =72.7 (64.4–79.6) | MR | Lassen A et al. Am J Gastroenterol. 2006 | ||
| K50 | Crohn’s disease | 1988–1992 (IN; A/B | 563.01 | 281 | PPV =97.2 (94.5–98.6); Se =94.4 (89.4–97.1) | MR and PD for PPV; PD for Se | Fonager K et al. Scand J Gastroenterol. 1996 |
| K51 | Ulcerative colitis | 1988–1992 (IN; A/B | 563.19, 569.04 | 506 | PPV =90.3 (87.4–92.6); Se =93.7 (90.2–96.0) | MR and PD for PPV; PD for Se | Fonager K et al. Scand J Gastroenterol. 1996 |
| K59.0 | Constipation after stroke | 2003–2006 (IN; A/B) | K59.0 (after admission to stroke units and age ≥18 y) | 7 | PPV =42.9 (15.8–75.0); NPV =84.7 (81.6–87.4); Se =3.9 (1.3–10.8); Sp =99.4 (98.2–99.8) | MR | Ingeman A et al. Clin Epidemiol. 2010 |
| K70 | Mild liver disease | 1998–2007 (IN/OUT; A) | B18, K70.0–K70.3, K70.9, K71, K73–K74, K76.0 | 50 | PPV =100 (92.9–100) | DS | Thygesen SK et al. BMC Med Res Methodol. 2011 |
| K70 | Liver cirrhosis | 1985–1989 (IN; A/B | 571.09, 571.90–571.92, 571.99 | 198 | PPV =85.4 (79.8–89.6); Se =93.2 (85.9–96.8) | MR and PD for PPV; PD for Se only | Vestberg K. J Med Syst. 1997 |
| K70.3 | Alcoholic cirrhosis | 1997–2005 (IN/OUT/ED; | 571.09; K70.3 (+ a liver biopsy during that hospital contact: SNOMED codes T56xxx) | 516 | PPV =77.7 (73.9–81.1) | PD | Jepsen P et al. BMC Gastroenterol. 2008 |
| K72 | Moderate/severe liver disease | 1998–2007 (IN/OUT; A) | B15.0, B16.0, B16.2, B19.0, K70.4, K72, K76.6, I85 | 50 | PPV =100 (92.9–100) | DS | Thygesen SK et al. BMC Med Res Methodol. 2011 |
| K572–K579 | Diverticular disease | 1999–2008 (IN/OUT; A/B | K572–K579 | 100 | PPV =98.0 (93.0–99.5) | Discharge summary/outpatient notes | Erichsen R et al. Clin Exp Gastroenterol. 2010 |
| K859 | Acute pancreatitis | 1981–2000 (IN; | 577.00–577.09; K85.9 | 99 | PPV1981–2000 =82 (72.8–88.9) | MR | Floyd A et al. Scand J Gastroenterol. 2002 |
| L00–L99: Diseases of the skin and subcutaneous tissue | |||||||
| L89.9 | Decubitus after stroke | 2003–2006 (IN; A/B) | L89.9 (after admission to stroke units and age ≥18 y) | 8 | PPV =50.0 (21.5–78.5); NPV =96.6 (94.7–97.8); Se =18.2 (5.1–47–7); Sp =99.5 (98.4–99.8) | MR | Ingeman A et al. Clin Epidemiol. 2010 |
| M00–M99: Diseases of the musculoskeletal system and connective tissue | |||||||
| M00 | Septic arthritis after knee arthroscopy | 1998–2000 or 2003–2005 (IN; n/a) | M00, T81.4, T81.8–T81.9 (+ KNGA, KNGD, KNGE, KNGF, or KNGH) | 450 | Se =66.9 (59.2–73.8) | Danish Patient Insurance Association | Majholm B et al. Dan Med J. 2012 |
| M05 | Rheumatoid arthritis (women) | 1977–2006 | 712.19, 712.39, 712.59; M05, M06 | 40 | PPV =75.0 (59.8–85.8) | MR | Atladottir HO et al. Pediatrics. 2009 |
| Rheumatoid arthritis | 1977–2001 (IN/OUT; A/B) | 712.19, 712.39, 712.59; M05–M06 (except M06.1) (age >15 y) | 217 | PPV =59.0 (52.3–65.3), higher for rheumatology departments and inpatient admissions; Se =26.4 (17.6–37.6) | PPV using MR/Se using MR-confirmed self-reported cases in the Danish Nationwide Twin Population cohort | Pedersen M et al. Eur J Epidemiol 2004 | |
| M05 | Connective tissue disease | 1998–2007 (IN/OUT; A) | M05–M06, M08–M09, M30–M36, D86 | 50 | PPV =98.0 (89.5–100) | DS | Thygesen SK et al. BMC Med Res Methodol. 2011 |
| Connective tissue disease following breast implant | 1977–1993 (IN; A/B) | 712.09–712.39, 712.59, 716.09, 716.19, 734.00–734.09, 734.19, 734.90 | 35 | PPVDefinite =82.9 (67.3–91.9) | MR | Friis S et al. Ann Plast Surg. 1997 | |
| M510 | Lumbar disc prolapse | 1990–1991 (IN; A) | 725.11 | 98 | PPV =90 | MR | Jensen MV et al. Ugeskr laeger. 1995 |
| M87 | Osteonecrosis of the jaw in postmenopausal osteoporosis | 2005–2010 (IN/OUT; | K04.6, K10.2, K10.3, M87 | 60 | PPV =31.7 (21.3–44.2) | MR | Gammelager H et al. Clin Epidemiol. 2013 |
| Osteonecrosis of the jaw among cancer patients | 2005–2009 (IN/OUT; | K04.6, K10.2–K10.3 (except K10.2E–F), M87 + prior C00–C97 (except C44) | 91 | PPV =19.8 (12.9–29.1) | MR | Gammelager H et al. Cancer Epidemiol. 2012 | |
| Osteonecrosis of the jaw in patients with cancer diagnosed within 5 y | 2005–2010 | K04.6, K10.2, K10.3, M87 + prior C15–C29, C33–C43, C45–C97 (excl head and neck cancers and non-melanoma skin cancer) + departments of oral and maxillofacial surgeries | 197 | PPV =42.1 (35.5–49.1); Se =73.3 | MR | Ehrenstein V et al. Pharmacoepidemiol Drug Saf. 2014 | |
| N00–N99: Diseases of the genitourinary system | |||||||
| N00 | Moderate to severe renal Disease | 1998–2007 (IN/OUT; A) | I12, I13, N00–N05, N07, N11, N14, N17–N19, Q61 | 50 | PPV =100 (92.9–100) | DS | Thygesen SK et al. BMC Med Res Methodol. 2011 |
| N30.0 | Urinary infection after stroke | 2003–2006 (IN; A/B) | N30.0, N30.8, N30.9, N10 (after admission to stroke units and age ≥18 y) | 39 | PPV =76.9 (61.7–87.4); NPV =70.9 (67.0–74.6); Se =14.3 (9.8–20.4); Sp =98.0 (96.1–99.0) | MR | Ingeman A et al. Clin Epidemiol. 2010 |
| N80 | Endometriosis | 1977–1988 (IN; A/B) | 625.3 (among women undergoing gynecological surgery) | 427 | PPV =95.1 (92.6–96.8); NPV =89.3 (88.4–90.2); Se =45.8 (42.6–49.1); Sp =99.5 (99.2–99.7) | DS | Kjaergaard J et al. J Clin Epidemiol. 2002 |
| N830–N832 | Ovarian cysts | 1977–1988 (IN; A/B) | 615.2 | 601 | PPV =75.5 (72.0–78.8); NPV =87.2 (86.2–88.2); Se =45.1 (42.1–48.2); Sp =96.2 (95.6–96.8) | DS | Kjaergaard J et al. J Clin Epidemiol. 2002 |
| N91–N94 | Bleeding disorders | 1977–1988 (IN; A/B) | 626 (among women undergoing gynecological surgery) | 986 | PPV =93.9 (92.3–95.2); NPV =95.2 (94.5–95.8); Se =83.0 (80.7–85.1); Sp =98.4 (98.0–98.8) | DS | Kjaergaard J et al. J Clin Epidemiol. 2002 |
| O00–O99: Pregnancy, childbirth and puerperium | |||||||
| O021–03 | Abortion | 1984 (IN; A/B | 642, 644, and 631, 643, 645 if also registered in Register of Legally | 359 | PPV =46–69 for confirmation on four-digit level | DS | Schmidt L et al. Ugeskr laeger. 1989 |
| Spontaneous abortion | 1980–2008 (IN/OUT/ED; | 634.6, 645.1, 643.8, 643.9; O02.1A, O03 | 117 | PPVAll =97.4 (92.7–99.1) | DS | Lohse SR et al. Clin Epidemiol. 2010 | |
| O04–06 | Provoked abortion | 1994 (IN; | O04–06 | 17,764 | PPV =93.5 (93.2–93.9); Se =97.0 (96.8–97.3) | Register of Legally Induced Abortions | Krebs L et al. Ugeskr laeger. 1997 |
| O139 | Gestational hypertension | 1998–2000 (IN/OUT; A/B | O13.9 | 3,039 | PPV =56.3 (33.2–76.9); NPV =97.3 (96.7–97.8); Se =10.0 (5.4–17.9); Sp =99.8 (99.5–99.9) | MR | Klemmensen ÅK et al. Am J Epidemiol. 2007 |
| O139 | Hypertensive disorders of pregnancy | 1998–2000 (IN/OUT; A/B | O13.9–O14.1–O14.2, O14.9–O15.0 | 3,039 | PPV =88.8 (81.0–93.6); NPV =96.9 (96.2–97.5); Se =48.9 (41.6–56.2); Sp =99.6 (99.3–99.8) | MR | Klemmensen ÅK et al. Am J Epidemiol. 2007 |
| 1982–1987 (IN; A/B | n/a | 112 | PPV =70; | MR | Kristensen J et al. J Clin Epidemiol 1996 | ||
| O14 | Preeclampsia | 1998–2000 (IN/OUT; A/B | O14.0–O14.2, O14.9–O15.0 | 3,039 | PPV =74.4 (64.0–82.6); NPV =99.1 (98.7–99.4); Se =69.3 (59.0–78.0); Sp =99.3 (98.9–99.5) | MR | Klemmensen ÅK et al. Am J Epidemiol. 2007 |
| 2001 (IN; A/B | O13–14 | 39 | PPV =69.2 (53.6–81.4); NPV =98.6 (97.7–99.2); Se =64.3 (49.2–77.0); Sp =98.9 (98.1–99.4) | MR | Langhoff-Ross J et al. 2003 | ||
| O24 | Gestational diabetes | 2001 (IN; A/B | O24 | 21 | PPV =100 (84.5–100); NPV =99.7 (99.2–99.9); Se =87.5 (69.0–95.7); Sp =100 (99.7–100) | MR | Langhoff-Ross J et al. 2003 |
| O32 | Malpresentation of fetus | 2001 (IN; A/B | O32 | 37 | PPV =48.7 (33.5–64.1); NPV =99.3 (98.6–99.6); Se =69.2 (50.0–83.5); Sp =98.3 (97.3–98.9) | MR | Langhoff-Ross J et al. 2003 |
| O342 | Previous cesarean section | 2001 (IN; A/B | O34.2, Z35.8E | 84 | PPV =90.5 (82.3–95.1); NPV =97.7 (96.6–98.5); Se =76.0 (66.8–83.3); Sp =99.2 (98.5–99.6) | MR | Langhoff-Ross J et al. 2003 |
| O365 | Small for gestational age | 2001 (IN; A/B | O36.5 | 25 | PPV =56.0 (37.1–73.3); NPV =99.5 (98.8–99.8); Se =70.0 (48.1–85.5); Sp =99.0 (98.2–99.4) | MR | Langhoff-Ross J et al. 2003 |
| O409 | Polyhydramnios | 1982–1987 (IN; A/B | n/a | 19 | PPV =74; | MR | Kristensen J et al. J Clin Epidemiol 1996 |
| O42 | Premature rupture of membranes | 2001 (IN; A/B | O42.3 | 50 | PPV =64.0 (50.1–75.9); NPV =98.5 (97.6–99.1); Se =66.7 (52.5–78.3); Sp =98.3 (97.4–98.9) | MR | Langhoff-Ross J et al. 2003 |
| O44 | Placenta previa | 1982–1987 (IN; A/B | n/a | 53 | PPV =70; | MR | Kristensen J et al. J Clin Epidemiol 1996 |
| O45 | Abruptio placenta | 1982–1987 (IN; A/B | n/a | 172 | PPV =69; | MR | Kristensen J et al. J Clin Epidemiol 1996 |
| O489 | Prolonged pregnancy | 2001 (IN; A/B | O48.9 | 53 | PPV =67.9 (54.5–78.9); NPV =99.4 (98.7–99.7); Se =83.7 (70.0–91.9); Sp =98.4 (97.5–99.0) | MR | Langhoff-Ross J et al. 2003 |
| O62 | Abnormalities of forces of labor | 2001 (IN; A/B | O62.2 | 317 | PPV =85.5 (81.2–88.9); NPV =88.2 (85.7–90.2); Se =73.8 (69.1–78.1); Sp =94.0 (92.0–95.4) | MR | Langhoff-Ross J et al. 2003 |
| O641 | Obstructed labor due to breech presentation | 2001 (IN; A/B | O64.1, O32 | 46 | PPV =76.1 (62.1–86.1); NPV =99.4 (98.7–99.7); Se =83.3 (69.4–91.7); Sp =99.0 (98.2–99.4) | MR | Langhoff-Ross J et al. 2003 |
| O654 | Obstructed labor due to fetopelvic disproportion | 2001 (IN; A/B | O65.4 | 21 | PPV =85.7 (65.4–95.0); NPV =98.6 (97.8–99.2); Se =54.6 (38.0–70.2); Sp =99.7 (99.2–99.9) | MR | Langhoff-Ross J et al. 2003 |
| O68 | Fetal distress | 2001 (IN; A/B | O68 | 166 | PPV =63.3 (55.7–70.2); NPV =97.4 (96.2–98.2); Se =80.8 (73.2–86.6); Sp =93.9 (92.2–95.2) | MR | Langhoff-Ross J et al. 2003 |
| O700 | First degree perineal laceration | 2001 (IN; A/B | O70.0 | 174 | PPV =50.6 (43.2–57.9); NPV =90.5 (88.4–92.2); Se =49.2 (41.9–56.4); Sp =90.9 (88.9–92.6) | MR | Langhoff-Ross J et al. 2003 |
| O701 | Second degree perineal laceration | 2001 (IN; A/B | O70.1 | 91 | PPV =46.2 (36.3–56.3); NPV =96.3 (95.0–97.3); Se =52.5 (41.7–63.1); Sp =95.3 (93.9–96.4) | MR | Langhoff-Ross J et al. 2003 |
| O710 | Rupture of uterus | 1980–1987 (IN; A/B | O71.0–O71.1 | 956 | PPV =13.5 (11.5–15.8) | MR | Devantier A et al. Ugeskr Læger 1991 |
| O714 | Vaginal laceration | 2001 (IN; A/B | O71.4 | 56 | PPV =8.9 (3.9–19.3); NPV =99.7 (99.2–99.9); Se =62.5 (30.6–86.3); Sp =95.4 (94.1–96.5) | MR | Langhoff-Ross J et al. 2003 |
| O72 | Postpartum hemorrhage | 2001 (IN; A/B | O72 | 57 | PPV =52.6 (39.9–65.0); NPV =98.6 (97.7–99.2); Se =66.7 (52.1–78.6); Sp =97.5 (96.4–98.3) | MR | Langhoff-Ross J et al. 2003 |
| P00–P96: Certain conditions originating in the perinatal period | |||||||
| P22 | Infant respiratory distress syndrome | 1977–2008 (IN; | 776.19; P22.0 | 90 | PPVOverall =81.1 (71.8–87.9); PPVpreterm infants born <37 wks =89.2 (79.4–94.7) for | MR | Thygesen SK et al. Clin Epidemiol. 2013 |
| P57.0 | Kernicterus | 1994–2003 (IN; A/B | P57.0, P57.7, P57.9 (+ gestational age ≥35 y) | 15 | PPV =40.0 (19.8–64.3) | MR | Maimburg RD et al. Acta Obstet Gynecol Scand. 2009 |
| Q00–Q99: Congenital malformations, deformations and chromosomal abnormalities | |||||||
| Q20 | Congenital cardiac malformations | 2000–2008 (IN/OUT/ED; | Q20–25, except Q20.9, Q21.9, Q22.9, Q23.9, Q24.9, Q25.9 | 3,536 | PPV =98.4 (98.0–99.8) | MR | Agergaard P et al. Clin Epidemiol. 2011 |
| 1994–2002 (IN/OUT; | Q20–26 | 418 | PPV =89.0 (85.6–91.7) | MR; echo, autopsy | Jepsen B et al. Int J Risk Saf Med. 2006 | ||
| 1991–1994 (IN; A/B | 740–759; Q00–99 (except 755.69, 752.10–752.19, Q53, Q65) | 744 | PPV =88.2 (85.7–90.3); Se =89.9 (87.5–91.9) | MR; Medical Birth Registry; National Registry of Congenital Abnormalities | Larsen H et al. Scand J Public Health. 2003 | ||
| Q53 | Cryptorchidism | 1995–2009 (n/a; A) | Q53 | 452 | PPV =80.3 (76.4–83.7) | MR | Jensen MS et al. J Urol. 2012 |
| Q54 | Hypospadias | 1989–2003 (IN; | 752.20–752.29; Q54 | 43 | PPV =93.0 (81.4–97.6) | MR | Pedersen L et al. Int J Med Sci. 2006 |
| Q96 | Turner syndrome | 1984–1993 (IN; A/B) | 310.54, 311.54, 312.54, 313.54, 314.54, 315.54, 759.50 | 237 | PPV =68.8 (62.6–74.3) | MR; Cytogenetic Central Register | Gravholt CH et al. J Clin Epidemiol. 1998 |
| R00–R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | |||||||
| R29.7 | Falls after stroke | 2003–2006 (IN; A/B) | R29.7, EUHE (after admission to stroke units and age ≥18 y) | 1 | PPV =0.0 (0.0–79.4); NPV =84.5 (81.4–87.2); Se =0 (0–5.1); Sp =99.8 (98.9–100) | MR | Ingeman A et al. Clin Epidemiol. 2010 |
| R56 | Febrile seizures | 1990–2001 (IN/OUT; A/B | 780.21; R56.0 | 249 | PPV =92.8 (88.8–95.4); NPV =98.6 (98.2–98.8); Se =71.5 (66.4–76.2); Sp =99.7 (99.6–99.8) | MR/telephone interviews | Vestergaard M et al. J Clin Epidemiol. 2006 |
| R570 | Shock overall | 2005–2012 (IN; A/B) | R57.0–R57.2, A41.9A (+BFHC92, BFHC93 excl BFHC93E-H, BFHC95) | 158 | PPV =86.1 (79.8–90.6); PPV+ Inotrope/vasopressor =93.1 (84.8–97.0) | MR | Lauridsen MD et al. BMC Med Res Methodol. 2015 |
| R570 | Cardiogenic shock | 2005–2012 (IN; A/B) | R570 (+ BFHC92, BFHC93 excl BFHC93E-H, BFHC95) | 46 | PPV =93.5 (82.5–97.8); PPV+ Inotrope/vasopressor =96.0 (80.5–99.3) | MR | Lauridsen MD et al. BMC Med Res Methodol. 2015 |
| R571 | Hypovolemic shock | 2005–2012 (IN; A/B) | R571 (+ BFHC92, BFHC93 excl BFHC93E-H, BFHC95) | 34 | PPV =70.6 (53.8–83.2); PPV+ Inotrope/vasopressor =69.2 (42.4–87.3) | MR | Lauridsen MD et al. BMC Med Res Methodol. 2015 |
| R572 | Septic shock | 2005–2012 (IN; A/B) | R572, A41.9A (+ BFHC92, BFHC93 excl BFHC93E-H, BFHC95) | 78 | PPV =69.2 (58.3–78.4); PPV+ Inotrope/vasopressor =82.4 (66.5–91.7) | MR | Lauridsen MD et al. BMC Med Res Methodol. 2015 |
| S00–T98: Injury, poisoning and certain other consequences of external causes | |||||||
| S02 | Head injury | 1982–1985 | 800–803, 850–854 | .50 | PPV =90 | MR | Sørensen HT et al. Ugeskr Laeger. 1987 |
| S73 | Traumatic hip dislocation | 1989–1990 (IN; n/a) | 835.99 | 755 | PPV =16.0 (13.6–18.8) | MR; X-rays | Hougaard K et al. Ugeskr Laeger 1992 |
| T634F | Anaphylactic shock after bee sting | 1973–1985 (IN; A/B | 999.49 | n/a | Se =60.0 (38.7–78.1) | MR | Sørensen HT et al. Allergy. 1989 |
| T84.5 | Periprosthetic hip joint infection | 2003–2008 (IN; A/B | T84.5 + hip-specific NCSP code + departments of orthopedic surgery. Infection-specific surgery: KNFS19, KNFS49, KNFU89, KNFW69 | 283 | PPV =84.8 (80.2–88.5); PPV+ Infection-specific surgical code =86.1 (80.5–90.3) | MR | Lange J et al. Hip Int. 2015 |
| Z00–Z99: factors influencing health status and contact with health services | |||||||
| Z131 | Glucose tolerance test | 2001 (IN; A/B | Z13.1 | 111 | PPV =57.7 (48.4–66.4); NPV =94.8 (93.2–96.0); Se =54.7 (45.7–63.4); Sp =95.4 (93.9–96.5) | MR | Langhoff-Ross et al. 2003 |
| Z358D | High-risk pregnancy due to previous complicated pregnancy/birth | 2001 (IN; A/B | Z35.8D | 29 | PPV =34.5 (19.9–52.7); NPV =97.5 (96.5–98.3); Se =27.0 (15.4–43.0); Sp =98.3 (97.3–98.9) | MR | Langhoff-Ross et al. 2003 |
| Z358E | High-risk pregnancy due to previous cesarean section | 2001 (IN; A/B | Z35.8E | 77 | PPV =88.3 (79.3–93.7); NPV =97.3 (96.1–98.1); Se =70.1 (60.4–78.3); Sp =99.1 (98.4–99.5) | MR | Langhoff-Ross et al. 2003 |
| Other conditions | |||||||
| Charlson Comorbidity Index conditions | 1998–2007 (IN/OUT; A) | See individual diseases | 950 | PPV =98.0 (96.9–98.7) | DS | Thygesen SK et al. BMC Med Res Methodol. 2011 | |
| Surgery (K) | |||||||
| KDC | Surgery for cholesteatoma | 1977–2007 (IN) | 20380–20700, 20990, KDC, KDD, KDE, KDFD30 (except KDCA10, KDCA20, KDCW00, KDEE, KDEE00) | 107 | PPV =98.1 (93.4–95.5) | Surgical records | Djurhuus et al. Dan Med Bull. 2010 |
| KHAD10 | Breast implant | 1977–1992 (IN) | 38500, 38540 | 2,576 | PPV =100 (99.9–100) | MR | Friis S et al. Ann Plast Surg. 1997 |
| 1977–1989 (IN; n/a) | 3854 | 71 | PPV =100 (94.9–100) | MR | McLaughlin JK et al. J Natl Cancer Inst. 1995 | ||
| KHAD00 | Breast augmentation | 1977–1989 (IN; n/a) | 3850 | 74 | PPV =94.6 (86.9–97.9) | MR | McLaughlin JK et al. J Natl Cancer Inst. 1995 |
| KJAP | Intraperitoneal adhesiolysis | 1977–1988 (IN) | 40480 | 341 | PPV =95.9 (93.2–97.5); NPV =99; | DS | Kjaergaard J et al. J Clin Epidemiol. 2002 |
| KJBC00 | Gastroesophageal antireflux operation | 1997–1999 (IN) | KJBC00, KJBC01 (age ≥18 y + admission >3 days or readmission or in-hospital death) | 243 | PPV =100 (98.4–100) | MR | Holte K et al. Ugeskr Laeger. 2001 |
| KJEA | Appendectomy | 1977–1988 (IN) | 43000 | 899 | PPV =99.0 (98.1–99.5); NPV =100; | DS | Kjaergaard J et al. J Clin Epidemiol. 2002 |
| KJKA2 | Cholecystectomy | 2004–2005 (IN) | KJKA2 | 1,361 | PPV =99.9 (99.6–100) | MR | Harboe KM et al. |
| KKFC10 | Orchiectomy in prostate cancer patients | 2002–2008 (IN) | KKFC10, KKFC13, KKFC15 | 50 | PPV =100 (92.9–100); NPV =100 (92.9–100) | MR | Jespersen CG et al. Clin Epidemiol. 2012 |
| KKFH00 | Corrective surgery of cryptorchidism | 1995–2009 (IN) | KKFH00–KKFH01, KKFH10 | 249 | PPV =99.2 (97.1–99.8) | MR | Jensen MS et al. J Urol. 2012 |
| KL | Operations for gynecological cancer | 1977–1988 (IN) | Hysterectomy, oophorectomy, partial resection of the ovaries (unspecified codes) | n/a (≈10,182) | PPV =95 | MR | Kjaergaard J et al. J Epidemiol Biostat. 2001 |
| KLAD00A | Unilateral ovarian resection | 1977–1988 (IN) | 60040 | 1,128 | PPV =96.2 (94.9–97.2); NPV =98; | DS | Kjaergaard J et al. J Clin Epidemiol. 2002 |
| KLAD00B | Bilateral ovarian resection | 1977–1988 (IN) | 60060 | 195 | PPV =82.1 (76.1–86.8); NPV =100; | DS | Kjaergaard J et al. J Clin Epidemiol. 2002 |
| KLAE1 | Unilateral oophorectomy | 1977–1988 (IN) | 60100 | 399 | PPV =90.5 (87.2–93.0); NPV =99; | DS | Kjaergaard J et al. J Clin Epidemiol. 2002 |
| KLAE2 | Bilateral oophorectomy | 1977–1988 (IN) | 60120 | 87 | PPV =79.3 (69.7–86.5); NPV =100; | DS | Kjaergaard J et al. J Clin Epidemiol. 2002 |
| KLAF0 | Unilateral salpingo-oophorectomy | 1977–1988 (IN) | 60320 | 925 | PPV =95.8 (94.3–96.9); NPV =98; | DS | Kjaergaard J et al. J Clin Epidemiol. 2002 |
| KLAF1 | Bilateral salpingo-oophorectomy | 1977–1988 (IN) | 60300 | 534 | PPV =85.6 (82.4–88.3); NPV =99; | DS | Kjaergaard J et al. J Clin Epidemiol. 2002 |
| KLCD | Hysterectomy | 1977–1988 (IN) | 61020 | 3,162 | PPV =99.1 (98.7–99.4); NPV =96; | DS | Kjaergaard J et al. J Clin Epidemiol. 2002 |
| 1998–2000 (IN) | KLCC10, KLCC11, KLCC20, KLCD00, KLCD01, KLCD04, KLCD10, KLCD11, KLCD96, KLCD97, KLEF13 | 1,026 | PPV =99.8 (99.3–100) | DS | Møller C et al. Ugeskr laeger. 2002 | ||
| KLCD10 | Total vaginal hysterectomy | 1977–1988 (IN) | 61040 | 157 | PPV =73.9 (66.5–80.1); NPV =100; | DS | Kjaergaard J et al. J Clin Epidemiol. 2002 |
| KLCD11 | Supravaginal hysterectomy | 1977–1988 (IN) | 61000 | 184 | PPV =91.3 (86.3–94.6); NPV =100; | DS | Kjaergaard J et al. J Clin Epidemiol. 2002 |
| KLCD30 | Radical hysterectomy | 1977–1988 (IN) | 61100 | 91 | PPV =90.1 (82.3–94.7); NPV =100; | DS | Kjaergaard J et al. J Clin Epidemiol. 2002 |
| KLEF | Vaginal prolapse surgery | 1996–1998 (IN) | KLCD10, KLDC10, KLEF00, KLEF03, KLEF10, KLEF13, KLEF40, KLEF53, KLFE20 | 296 | PPV =69.3 (63.8–74.2) | MR | Ottesen M. Ugeskr Laeger 2009 |
| KMAA00A | Amniocentesis | 2001 (IN) | KMAA00A | 32 | PPV =75.0 (57.9–86.8); NPV =96.8 (95.6–97.7); Se =40.7 (29.1–53.4); Sp =99.3 (98.5–99.6) | MR | Langhoff-Ross et al. 2003 |
| KMAC00 | Labor induction with artificial rupture of membrane | 2001 (IN) | KMAC00 | 38 | PPV =55.3 (39.7–69.9); NPV =99.1 (98.3–99.5); Se =67.7 (50.1–81.4); Sp =98.5 (97.5–99.0) | MR | Langhoff-Ross et al. 2003 |
| KMAC05 | Artificial rupture of membrane during labor | 2001 (IN) | KMAC05 | 98 | PPV =80.6 (71.7–87.2); NPV =79.9 (77.3–82.2); Se =27.6 (22.8–33.1); Sp =97.7 (96.5–98.6) | MR | Langhoff-Ross et al. 2003 |
| KMAE | Vacuum extraction | 2001 (IN) | KMAE | 105 | PPV =97.1 (91.9–99.0); NPV =99.4 (98.7–99.7); Se =99.4 (88.4–97.4); Sp =99.7 (99.1–99.9) | MR | Langhoff-Ross et al. 2003 |
| KMBA | Removal of placenta | 2001 (IN) | KMBA | 33 | PPV =81.8 (65.6–91.4); NPV =99.3 (98.6–99.6); Se =77.1 (61.0–87.9); Sp =99.5 (98.8–99.8) | MR | Langhoff-Ross et al. 2003 |
| KMBC10 | Vaginal stitching | 2001 (IN) | KMBC10 | 87 | PPV =6.9 (3.2–14.2); NPV =99.8 (99.2–99.9); Se =75.0 (40.9–92.9); Sp =91.4 (89.4–93.0) | MR | Langhoff-Ross et al. 2003 |
| KMBC30 | Perineal stitching (excl sphincter) | 2001 (IN) | KMBC30 | 242 | PPV =60.3 (54.1–66.3); NPV =85.0 (82.1–87.4); Se =57.9 (51.8–63.9); Sp =86.2 (83.4–88.6) | MR | Langhoff-Ross et al. 2003 |
| KMBC33 | Perineal stitching (incl sphincter) | 2001 (IN) | KMBC33 | 25 | PPV =92.0 (75.0–97.8); NPV =98.5 (97.5–99.1); Se =62.2 (46.1–75.9); Sp =99.8 (99.2–99.9) | MR | Langhoff-Ross et al. 2003 |
| KMCA | Cesarean section | 2001 (IN) | KMCA | 185 | PPV =97.8 (94.6–99.2); NPV =99.6 (98.9–99.8); Se =97.8 (94.6–99.2); Sp =99.6 (98.9–99.8) | MR | Langhoff-Ross et al. 2003 |
| KN | Orthopedic surgery | 2004 (IN) | n/a | 554 | PPV =63.2 (59.1–67.1) | MR | Lass et al. Ugeskr laeger. 2006 |
| KPBE2–KPBE3 | Upper limb embolectomy | 1990–2002 (IN) | 86823–86824, PBE20, PBE30 | 1,134 | PPV =97.3 (96.2–98.1) | MR | Andersen LV et al. Clin Epidemiol. 2009 |
| KTMD00 | Episiotomy (incl stitching) | 2001 (IN) | KTMD00 | 130 | PPV =96.9 (92.4–98.8); NPV =99.6 (98.9–99.9); Se =97.7 (93.4–99.2); Sp =99.5 (98.8–99.8) | MR | Langhoff-Ross et al. 2003 |
| Other treatments (B) | |||||||
| BAFA7 | Infiltration anesthesia | 2001 (IN; A/B | BAFA7 | 338 | PPV =60.1 (54.8–65.1); NPV =85.9 (82.9–88.4); Se =70.2 (64.7–75.2); Sp =79.5 (76.2–82.4) | MR | Langhoff-Ross et al. 2003 |
| BAFA80 | Acupuncture | 2001 (IN; A/B | BAFA80 | 36 | PPV =75.0 (58.9–86.3); NPV =98.3 (97.3–98.9); Se =61.4 (46.6–74.3); Sp =99.1 (98.3–99.5) | MR | Langhoff-Ross et al. 2003 |
| BAFA81 | Inhalation anesthesia with nitrous oxide | 2001 (IN; A/B | BAFA81 | 85 | PPV =76.5 (66.4–84.2); NPV =80.6 (77.9–83.0); Se =25.9 (20.9–31.7); Sp =97.5 (96.1–98.4) | MR | Langhoff-Ross et al. 2003 |
| BAFA87 | Intracutaneous sterile water | 2001 (IN; A/B | BAFA87 | 20 | PPV =85.0 (64.0–94.8); NPV =96.0 (94.6–97.0); Se =29.3 (19.2–42.0); Sp =99.7 (99.1–99.9) | MR | Langhoff-Ross et al. 2003 |
| BFHC92 | Inotropes/vasopressors in shock patients | 2005–2012 (IN) | BFHC92–BFHC93, BFHC95 (excl BFHC93E-H) (+ R570–R572, A41.9A) | 72 | PPV =88.9 (79.6–94.3) | MR | Lauridsen MD. BMC Med Res Methodol. 2015 |
| BGDA | Mechanical ventilation in ICU patients | 2005–2010 (IN) | NABE/NABB + BGDA0 | 50 | PPV =100 (92.9–100) | MR | Blichert-Hansen et al. Clin Epidemiol. 2013 |
| BJFD | Acute dialysis in ICU admitted patients | 2005–2010 (IN) | NABE/NABB + BJFD00/BJFD02 | 50 | PPV =98.0 (89.5–99.7) | MR | Blichert-Hansen et al. Clin Epidemiol. 2013 |
| BKHD0 | Uterotonic drugs following birth | 2001 (IN; A/B | BKHD0 | 57 | PPV =12.3 (6.1–23.3); NPV =98.8 (97.9–99.3); Se =35.0 (18.1–56.7); Sp =95.5 (94.1–96.6) | MR | Langhoff-Ross et al. 2003 |
| BKHD20 | Induction with prostaglandins | 2001 (IN; A/B | BKHD20 | 51 | PPV =98.0 (89.7–99.7); NPV =93.4 (91.8–94.7); Se =41.3 (33.0–50.2); Sp =99.9 (99.4–100) | MR | Langhoff-Ross et al. 2003 |
| BKHD3 | Labor induction medication | 2001 (IN; A/B | BKHD3 | 298 | PPV =83.6 (78.9–87.3); NPV =92.5 (90.5–94.1); Se =80.0 (75.3–84.1); Sp =94.0 (92.2–95.4) | MR | Langhoff-Ross et al. 2003 |
| BKQA0 | Bath | 2001 (IN; A/B | BKQA0 | 67 | PPV =85.1 (74.7–91.7); NPV =74.5 (71.6–77.1); Se =18.6 (14.7–23.4); Sp =98.6 (97.5–99.3) | MR | Langhoff-Ross et al. 2003 |
| BWGC1 | Radiation therapy to the bone in patients with prostate (P) or breast (B) cancer | 2000–2005 | BWGC1 (+ C61.9/C50) | 16 P; 10 B | PPVP =75.0 (50.5–89.8); NPVP =83.3 (74.0–89.8); PPVB =60.0 (31.3–83.2); NPVB =95.6 (89.1–98.3); SeP =46.2 (28.8–64.5); SpP =94.6 (86.9–97.9); SeB =60.0 (31.3–83.2); SpB =95.6 (89.1–98.3) | MR | Jensen AØ et al. Clin Epidemiol. 2009 |
| BWHA | Chemotherapy for colorectal cancer | 2009–2010 | BWHA1–BWHA2, BOHJ19B | 35 | PPV =97.1 (85.5–99.5); NPV =93.3 (70.2–98.8); Se =97.1 (85.5–99.5); Sp =93.3 (70.2–98.8) | MR; hospital pharmacy production systems | Lund JL et al. Clin Epidemiol. 2013 |
| BWHB40 | Bisphosphonate therapy in cancer patients | 2005–2009 | BWHB40 | 60 | PPV =98.3 (91.1–99.7) | MR | Nielsson MS et al. Clin Epidemiol 2012 |
| BWHC | Gonadotropin-releasing hormone agonist in prostate cancer patients | 2002–2008 | BWHC | 100 | PPV =93.0 (86.3–96.6); NPV =94.0 (87.5–97.2); Se =93.9 (87.4–97.2); Sp =93.1 (86.4–96.6) | MR | Jespersen CG et al. Clin Epidemiol. 2012 |
| ATC codes (M) | |||||||
| MJ06BB16 | Palivizumab | 1999–2010 | MJ06BB16 | 182 | PPVMR =91.7 (80.4–96.7); NPVMR =59.0 (53.3–64.5); SeMR =97.8 (20.5–33.9); SpMR =26.7 (94.4–99.1); PPVPR =90.7 (85.6–94.1); NPVPR =98.4 (97.9–98.9); SePR =79.7 (73.7–84.6); SpPR=99.4 (99.0–99.6) | MR; PR | Haerskjold A et al. Clin Epidemiol. 2015 |
| Anesthesia and intensive care (N) | |||||||
| NAAC | General anesthesia | 2001 (IN) | NAAC | 20 | PPV =40.0 (21.9–61.3); NPV =95.9 (94.6–97.0); Se =15.1 (7.9–27.1); Sp =98.9 (98.1–99.4) | MR | Langhoff-Ross et al. 2003 |
| NAAD0 | Epidural nerve block | 2001 (IN) | NAAD0 | 24 | PPV =75.0 (55.1–88.0); NPV =91.8 (89.9–93.3); Se =17.7 (11.5–26.2); Sp =99.4 (98.6–99.7) | MR | Langhoff-Ross et al. 2003 |
| NAAD1 | Spinal anesthesia | 2001 (IN) | NAAD1 | 35 | PPV =77.1 (61.0–87.9); NPV =91.6 (89.8–93.1); Se =22.7 (16.1–31.0); Sp =99.2 (98.4–99.6) | MR | Langhoff-Ross et al. 2003 |
| NAAD43 | Pudendal nerve block | 2001 (IN) | NAAD43 | 40 | PPV =70.0 (54.6–81.9); NPV =95.9 (94.4–97.0); Se =43.1(31.8–55.2); Sp =98.6 (97.6–99.2) | MR | Langhoff-Ross et al. 2003 |
| NABB | Intensive care unit admission | 2005–2010 (IN) | NABB, NABE | 47 | PPV =87.2 (74.8–94.0) | MR | Blichert-Hansen et al. Clin Epidemiol. 2013 |
| UXCC00A | Cardiac CT Angiography | 2008–2012 | UXCC00A | 289 | PPV =100 (98.7–100) | MR | Nielsen LH et al. Clin Epidemiol. 2014 |
| UXUD88A | Fetal umbilical artery flow velocity measurement | 2001 (IN) | UXUD88A | 63 | PPV =77.8 (66.1–86.3); NPV =94.9 (93.4–96.1); Se =47.6 (38.2–57.1); Sp =98.6 (97.7–99.2) | MR | Langhoff-Ross et al. 2003 |
Notes:
The ordering corresponds to the SKS browser, ie, ICD-10 for diagnoses and NOMESCO for surgery;
ICD codes without and with capital letters refer to ICD-8 and ICD-10 codes, respectively;
reflects the reviewed number of records in the DNPR (ie, the denominator in calculations of PPV). Among obstetric variables, we included only validation results based on >20 diagnoses;
confidence intervals were calculated using Wilson’s score method;
information not specified in validation papers, but confirmed through correspondence with authors. Unspecified and unconfirmed data are listed as not available (n/a);
recalculation of confidence intervals using Wilson’s score method not possible due to insufficient data;
confidence limit equals 100 due to rounding.
Abbreviations: A, primary diagnosis; AC, anticoagulant therapy; B, secondary diagnosis; COPD, chronic obstructive pulmonary disease; CT, computed tomography; d, day; DVT, deep venous thrombosis; DANMONICA, Danish Monitoring Trends and Determinants in Cardiovascular Disease project; DCR, Danish Cancer Registry; DNPR, Danish National Patient Registry; DS, discharge summaries; echo, echocardiography; ECG, electrocardiography; ED, emergency department; GP, general practitioner; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; ICD, International Classification of Diseases; ICU, intensive care unit; IN, inpatient contact; LABKA, Clinical Laboratory Information System Database; mo, month; MR, medical records; MRI, magnetic resonance imaging; MS, multiple sclerosis; n/a, not available; NPV, negative predictive value; OUT, outpatient contact; PD, Pathology Registry; PE, pulmonary embolism; PPV, positive predictive value; PR, Prescription Registry; PSA, prostate specific antigen; Se, study sample sensitivity; Sp, study sample specificity; ultrasound, ultrasonography; y, year(s); V-P, ventilation-perfusion; VTE, venous thromboembolism; NOMESCO, Nordic Medico-Statistical Committee; wks, weeks.